Study finds promising first evidence of targeted therapy for NRAS-mutant melanoma

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and activate the immune system, offering the first targeted approach for patients with NRAS-mutant melanoma, an aggressive form of skin cancer with limited treatment options beyond immune checkpoint inhibitors.

👉 Full Story